← All trials
NCT05815758
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2023
- Primary completion
- Sep 18, 2023
- Completion date
- Sep 18, 2023
- First posted
- Apr 18, 2023
- Last posted
- Jul 10, 2025
- Enrollment
- 512
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bausch & LombLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.